Thymosin Alpha-1

28-amino acid peptide naturally produced by the thymus. Activates toll-like receptors (TLR2, TLR9) on dendritic cells, enhances T-cell differentiation, and stimulates natural killer cell activity. FDA-designated orphan drug. Approved in over 35 countries for hepatitis B and C and as an immune adjuvant.

Half-life

2 hours

Bioavailability

Systemic via subcutaneous injection

Route

subcutaneous

Evidence tier

T1 — Multiple RCTs

Optimization pillars

anti-aging

References

2 peer-reviewed

Dose ranges

Three tiers ordered by aggressiveness. Tier chips on every OPTIMIZE intervention let you filter the catalog by your evidence tolerance.

conservative

0.8–1.6 mg twice/week

Immune maintenance

moderate

1.6 mg twice/week

Standard clinical dose (Zadaxin)

aggressive

1.6–3.2 mg daily for acute immune challenge

Intensive protocol

Monitoring

wbc
thyroid-panel

Contraindications

organ-transplant-recipients
immunosuppressive-therapy

References

PMID:17045077Thymosin alpha 1 — a peptide immune response modifier with broad clinical applications — Expert Opin Biol Ther, 2006
PMID:20041220Thymalfasin (thymosin alpha 1) for the treatment of hepatitis B and C — Expert Opin Biol Ther, 2009

Notes

Thymosin Alpha-1 is the most clinically validated immune peptide in existence. Approved in 35+ countries. Used in hepatitis treatment protocols with published RCTs. Used as a vaccine adjuvant. Used during COVID-19 as an immunomodulator in critically ill patients. The distinction between this and a supplement-grade immune booster is the difference between published clinical trial data and marketing copy. Zadaxin (the brand name) has the evidence. Generic TA1 from research suppliers does not have the same quality assurance.

This is not medical advice

Discuss with a licensed clinician before starting, stopping, or changing any compound. This page documents what the research literature describes — it is not a prescription.

See Thymosin Alpha-1 in a protocol matched to you